Clinical Program BL8040

BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML

BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data

December 4th, 2017|Clinical Program BL8040|

BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration

Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations

July 10th, 2017|Clinical Program BL8040|

BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors

Genentech has submitted all three solid tumor trials planned under its cancer immunotherapy collaboration with BioLineRx. Studies will investigate the combination in pancreatic cancer, gastric cancer and non-small cell lung cancer (NSCLC)

June 1st, 2017|Clinical Program BL8040|

BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment

Results to date confirm that single injection of BL-8040 mobilizes sufficient amounts of cells required for allogeneic transplantation without need for G-CSF.

March 20th, 2017|Clinical Program BL8040|

BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

Initiation of Phase 3 registrational study expected in second half of this year. Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients

March 3rd, 2017|Clinical Program BL8040|

BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer

BL-8040 monotherapy resulted in increased infiltration of T cells into tumor. Data to be presented at the upcoming ASCO-GI conference; topline clinical results expected by H2 2018 as planned

January 17th, 2017|Clinical Program BL8040|

BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations

January 17th, 2017|Clinical Program BL8040|

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

November 3rd, 2016|Clinical Program BL8040|

BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer

Tel Aviv, Israel, September 20, 2016 – BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy […]

September 20th, 2016|Clinical Program BL8040|

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx’s BL-8040 in combination with Atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of […]

September 7th, 2016|Clinical Program BL8040, Recent News|